# **Avera Medical Group**

212 E. 11th St Sioux Falls, SD 57104 www.avera.org



# **Clinical Quality Measures**

2023 measurement year

Measure		Rating	Rate	
Adolescent Depression	PHQ-9 Utilization*	Below	57.00%	
	Follow-up at Six Months	-	-	
	Response at Six Months	-	-	
	Remission at Six Months	-	-	
	Follow-up at 12 Months	-	-	
	Response at 12 Months	-	-	
Ad	Remission at 12 Months	-	-	
	PHQ-9 Utilization*	Below	41.80%	
on	Follow-up at Six Months	Below Expected	0.00%	
essi	Response at Six Months	Below Expected	0.00%	
epr	Remission at Six Months	Below Expected	0.00%	
Adult Depression	Follow-up at 12 Months	Below Expected	3.80%	
Adı	Response at 12 Months	Below Expected	1.90%	
	Remission at 12 Months	Below Expected	0.00%	
Adolescent Mental Health and/or Depression Screening*		Below	83.20%	
Colorectal Cancer Screening		Below Expected	68.30%	
Optimal Asthma Control - Adults		Below Expected	0.00%	
Optin	nal Asthma Control - Children	Below Expected	0.00%	
Optimal Diabetes Care  HbA1c Control  BP Control  Daily Aspirin Use  Statin Use  Tobacco-Free		Expected Expected Below Expected Expected Expected Above Expected	<b>47.90</b> % 74.20% 78.90% 98.50% 89.00% 91.10%	
Optimal Vascular Care BP Control Daily Aspirin Use Statin Use Tobacco-Free		Expected Below Expected Expected Below Expected Above Expected	<b>52.60%</b> 77.90% 84.70% 84.40% 87.80%	

<sup>-</sup> Medical group not assigned to measure, did not have results, or did not meet reporting threshold

<sup>\*</sup>Measure not risk adjusted

#### **Avera Medical Group**

# Healthcare Effectiveness Data and Information Set (HEDIS) Measures

2023 measurement year

Measure	Rating	Rate
Avoidance of Antibiotic Treatment in Acute Bronchitis/Bronchiolitis	-	-
Breast Cancer Screening	-	-
Cervical Cancer Screening	-	-
Childhood Immunization Status (Combo 10)	-	-
Chlamydia Screening in Women	-	-
Controlling High Blood Pressure	-	-
Diabetes Eye Exam	-	-
Immunizations for Adolescents (Combo 2)	-	-
Follow-up Care for Children Prescribed ADHD Medication	Average	28.40%
Osteoporosis Management in Women Who Had a Fracture	-	-
Use of Spirometry Testing in the Assessment and Diagnosis of COPD	-	-

<sup>-</sup> Medical group not assigned to measure, did not have results, or did not meet reporting threshold

#### **Ratings**

*Above*: Medical group's actual rate is significantly above its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

Average: Medical group's actual rate is not statistically different than its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

**Below:** Medical group's actual rate is significantly below its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

#### **Total Cost of Care**

2023 measurement year

Population	Monthly Average Cost	Rating	Higher/Lower than Average
Overall	-	-	-
Adults	-	-	-
Pediatric	-	-	-